香雪XPH品牌怎么样 申请店铺

我要投票 香雪XPH在医疗器械行业中的票数:748 更新时间:2026-01-19
香雪XPH是哪个国家的品牌?「香雪XPH」是 广州市香雪制药股份有限公司 旗下著名品牌。该品牌发源于广东省广州市,由创始人王董在1986年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力香雪XPH品牌出海!将品牌入驻外推网,定制香雪XPH品牌推广信息,可以显著提高香雪XPH产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

香雪XPH怎么样

广州市香雪制药股份有限公司,始于1986年,广东省名牌,药典标准制定者,大中药健康产业领先者,现代化高新技术医药企业


“十里梅花浑似雪,萝岗香雪映朝阳。”诗人郭沫若赋诗赞赏的羊城八景之一“萝岗香雪”, 正是香雪制药的发祥地。1986年萝岗制药厂成立,1997年改制为广州市香雪制药股份有限公司,于2010年在中国深圳证券交易所公开发行股票(IPO)挂牌上市(股票代码:300147)。秉承“厚生、臻善、维新”的经营理念,公司把发展中药和实现中药现代化作为长远发展战略,经多年发展,现已成为拥有自主知识产权、自主品牌、自主创新能力的中药现代化的领军企业和技术企业,形成中药资源开发、中药先进制造、现代物流配送、新药创制的完整产业链。香雪制药先后在广东、北京、山西、四川、重庆、安徽、云南和宁夏等地设立十八间公司并投资兴建大规模的GMP生产基地和GAP药材种植基地,形成了新型中药饮片、中成药、功能健康食品(饮料)、养生保健等产品群所组成的大中药健康产业,在中国创造就业职位一万余个。

数字化中药

香雪制药致力于中药现代化的研究和实践,在中药现代化的关键技术——中成药质量控制技术、现代制剂技术、中药给药途径创新等研究取得丰硕成果及突破。香雪制药建立了以“现代中药指纹图谱质量控制技术”为核心的现代中药集成创新系统,应用指纹图谱质控技术,通过计算机相似度分析系统使得成分复杂的中药质量得到有效控制;应用中药临床循证医学评价方法,通过大样品、多中心的大规模临床数据评价使中药疗效准确与经济。香雪制药引进全球先进的信息管理系统,使中药生产经营、销售服务过程实现全面信息资源管理,对企业资源、供应链、客户关系、节能环保、智能办公等方面完成高度集成,使中药企业管理与大数据时代接轨。


Guangzhou Xiangxue Pharmaceutical Co., Ltd. started in 1986. It is a famous brand in Guangdong Province, a standard maker of Pharmacopoeia, a leader in the health industry of traditional Chinese medicine, and a modern high-tech pharmaceutical enterprise Luogang Xiangxue, one of the eight sceneries in Yangcheng, is the birthplace of Xiangxue pharmaceutical. Luogang pharmaceutical factory was established in 1986, and was restructured into Guangzhou Xiangxue Pharmaceutical Co., Ltd. in 1997. It was listed on the Shenzhen Stock Exchange in 2010 (Stock Code: 300147). Adhering to the business philosophy of "health, perfection and renovation", the company takes the development of traditional Chinese medicine and the modernization of traditional Chinese medicine as its long-term development strategy. After years of development, the company has become a leading enterprise and technical enterprise with independent intellectual property rights, independent brand and independent innovation ability, forming the development of traditional Chinese medicine resources, advanced manufacturing of traditional Chinese medicine, modern logistics and distribution, and the creation of new drugs A complete industrial chain. Xiangxue pharmaceutical has successively set up 18 companies in Guangdong, Beijing, Shanxi, Sichuan, Chongqing, Anhui, Yunnan and Ningxia and invested in the construction of large-scale GMP production base and gap medicine planting base, forming a large traditional Chinese medicine health industry composed of new traditional Chinese medicine pieces, proprietary Chinese medicine, functional health food (beverage), health care and other product groups, creating jobs in China More than 10000. Xiangxue pharmaceutical is committed to the research and practice of the modernization of traditional Chinese medicine, and has made fruitful achievements and breakthroughs in the key technologies of the modernization of traditional Chinese medicine, such as the quality control technology of traditional Chinese medicine, the modern preparation technology, and the innovation of the way of administration of traditional Chinese Medicine. Xiangxue pharmaceutical has established a modern integrated innovation system of traditional Chinese medicine with "modern fingerprint quality control technology" as the core. By using fingerprint quality control technology and computer similarity analysis system, the quality of traditional Chinese medicine with complex components can be effectively controlled. By using the clinical evidence-based medicine evaluation method of traditional Chinese medicine, the quality of traditional Chinese medicine can be effectively controlled through large-scale clinical data evaluation of large samples and multi centers The therapeutic effect is accurate and economical. Xiangxue pharmaceutical introduced the world's advanced information management system to realize the comprehensive information resource management in the process of Chinese medicine production, operation and sales service, and highly integrated the enterprise resources, supply chain, customer relationship, energy conservation and environmental protection, intelligent office, etc., so as to make the Chinese medicine enterprise management in line with the big data era.

本文链接: https://brand.waitui.com/5a03ebbad.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

上交所就瑞茂通相关事项下发监管工作函

36氪获悉,上交所晚间发布关于瑞茂通供应链管理股份有限公司相关事项的监管工作函,涉及对象为上市公司、董事、高级管理人员、控股股东及实际控制人,处理事由为就公司信息披露事项明确监管要求。

2小时前

盈方微:股票将于1月20日复牌

36氪获悉,盈方微公告,公司股票将于2026年1月20日开市时起复牌。此前,公司因筹划发行股份及支付现金购买资产并募集配套资金的事项存在不确定性,自2026年1月6日起停牌。公司决定不再推进对时擎智能科技有限公司的股权收购,但将继续推进对上海肖克利信息科技股份有限公司及富士德中国有限公司的收购,并募集配套资金。相关审计和评估工作尚未完成,公司将在完成后再次召开董事会审议并依法定程序召集股东会。

2小时前

荣耀Magic 8 Pro Air发布

36氪获悉,荣耀正式发布荣耀Magic8 Pro Air,4999元起售。据介绍,该产品搭载天玑9500第三代3nm全大核旗舰芯片。

2小时前

*ST天微:公司股票可能被终止上市

36氪获悉,*ST天微公告,公司于2025年4月30日披露了《关于实施退市风险警示暨停牌的公告》,公司因2024年度实现归属于上市公司股东的扣除非经常性损益前后的净利润孰低为负值,且2024年度实现扣除与主营业务无关的业务收入后营业收入将低于人民币1亿元,根据有关规定,公司股票于2025年5月6日起被实施退市风险警示。若公司出现《股票上市规则》第12.4.10条规定的情形,公司股票可能被上海证券交易所终止上市。请广大投资者注意投资风险。

2小时前

TCL科技:董事长提名王成担任公司首席执行官(CEO)

36氪获悉,TCL科技公告,因经营管理需要,公司董事长李东生提名王成担任公司首席执行官(CEO),全面负责日常经营管理工作,李东生不再兼任。2026年1月19日,第八届董事会第十九次会议审议通过该议案,王成任期至公司第八届董事会任期截止日。王成现任公司首席运营官,持有公司股票268,220股,符合任职条件。

2小时前

本页详细列出关于香雪XPH的品牌信息,含品牌所属公司介绍,香雪XPH所处行业的品牌地位及优势。
咨询